Clinical Trial Update: Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update on rivaroxaban for prevention of major cardiovascular events in coronary or peripheral artery disease; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Peripheral Artery Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Prevention & Control | Phase 3 | Status: COMPLETED | Results posted: 2018-10-05